In 2024, Adamed Discovery out-licensed its small-molecule MDM2 inhibitor, IND-ready programme AD-O21, now known as SA53, to Lamassu Biotech, a US-based specialist in translational oncology. This partnership builds on Adamed Discovery’s longstanding expertise in first-in-class oncology research and Lamassu’s capability to execute early-phase clinical development in leading American cancer centres. The molecule, discovered and optimised at Adamed Discovery, had already demonstrated robust anticancer activity in preclinical models of sarcomas, melanoma, and pediatric cancers, with a pharmacological profile suitable for first-in-human evaluation.
SA53 is a first-in-class, orally available MDM2 inhibitor designed to reactivate the body’s natural tumour suppressor pathway by restoring p53 function in cancers that retain a wild-type p53 gene. It is being developed primarily for p53 wild-type sarcomas and other solid tumours that are poorly served by current chemotherapy, targeting malignancies where MDM2 overexpression drives resistance and disease progression.
In July 2025, SA53 entered a Phase I/IIa clinical trial in the United States in collaboration with leading academic partners, marking the transition of this Adamed-originated programme into clinical development and reinforcing our strategy of advancing Polish innovation to patients worldwide through high-quality international partnerships.

In 2020, Adamed Discovery out-licensed a novel small-molecule GPCR blocker programme to Acadia Pharmaceuticals Inc., a US-based leader in neuroscience. The agreement grants Acadia exclusive global rights to further develop and commercialise the molecule, while Adamed retains defined rights in Poland and selected European markets. Built on a discovery effort originating in Adamed’s laboratories and advanced to a late preclinical stage, the transaction combines our expertise in original CNS drug discovery with Acadia’s capabilities in clinical development and global market access for neuropsychiatric therapies.
The out-licensed GPCR blocker is designed to modulate key neurotransmitter pathways implicated in severe psychiatric and neurodegenerative disorders, addressing areas of high unmet medical need that are central to both companies’ strategies. It emerges from Adamed’s long-standing research platform in GPCR receptor modulators, developed in close collaboration with the Jagiellonian University of Krakow and reflects our ambition to translate Polish science into first-in-class therapeutic options for patients worldwide.